For the treatment of the following
infections caused by sensitive bacteria:
Adults:
Respiratory tract infections:
Lobar and bronchopneumonia, acute and chronic cystic fibrosis, bronchiectasis, empyema, exacerbations of chronic obstructive pulmonary disease, bronchopulmonary infections in cystic fibrosis. Ciprofloxacin is not recommended as firstline therapy for the treatment of pneumococcal pneumonia. Ciprofloxacin may be used for treating Gram negative pneumonia.

Ear, nose and throat infections:
Mastoiditis, otitis media, malignant external otitis and acute exacerbation of chronic sinusitis, especially if due to gram-negative bacteria (including Pseudomanas spp.), chronic suppurative otitis media. Ciprofloxacin is not recommended for the treatment of acute tonsillitis.

Urinary tract infections:
Uncomplicated and complicated urethritis, cystitis, pyelonephritis, chronic bacterial prostatitis, epididymitis.

Genital tract infections:
Gonorrhea, including urethral, rectal and pharyngeal gonorrhea caused by ßlactamase producing organisms or organisms moderately sensitive to penicillin, salpingitis, endometritis, pelvic inflammatory disease, epididymo-orchitis including cases due to Neisseria gonorrhoeae, pelvic inflammatory disease including cases due to Neisseria gonorrhoeae.

Skin and soft tissue infections:
Infected ulcers, wound infections, abscesses, cellulitis, otitis externa, erysipelas, infected burns.

Bone and joint infections:
Osteomyelitis, septic arthritis.

Intra-abdominal infections:

Peritonitis, intra-abdominal abscesses.

Infections of the gastrointestinal tract:
Cholangitis, cholecystitis of the gall bladder, enteric fever (typhoid fever), infective diarrhea.

Severe systemic infections:
e.g. septicemia, bacteremia, peritonitis, infections in immuno-suppressed patients with hematological or solid tumours and in patients in intensive care units with specific problems such as infected burns.

Getcipro IV (Ciprofloxacin) is also used for:

• Treatment of infections or prophylaxis of infections in neutropenic patients.
• Inhalation anthrax post-exposure prophylaxis and curative treatment for
  persons requiring parenteral treatment. Drug administration should begin as
  soon as possible after suspected or confirmed exposure. Children and adolescents:
  Getcipro IV (Ciprofloxacin) is indicated for:
• The 2nd and 3rd line treatment of complicated urinary tract infections in
  patients 1-17 years of age.
• Pyelonephritis in patients 1-17 years
• The treatment of acute pulmonary exacerbation of cystic fibrosis associated
  with P. aruginosa infection in patients aged 5-17 years of age.
• For the reduction of the incidence or progression of disease following confirmed
  or suspected exposure to aerosolized Bacillus anthracis. Drug administration
  should begin as soon as possible after suspected or confirmed exposure.
  Getcipro IV (Ciprofloxacin) may also be used to treat severe infections in children
  and adolescents when this is considered to be necessary.